Molecular Partners Ag's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics

What is ROE for Molecular Partners Ag in the fourth quarter 2025?
Molecular Partners Ag recorded a cumulative net loss of $-99 million during 12 months ending in the fourth quarter 2025, resulting in a negative return on equity (ROE) of -103.25%.

Within the Biotechnology & Pharmaceuticals industry 78 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the third quarter 2025 from 0 to 4011.

What is ROE?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Equity ROE▼

None ▼

Return on Equity ROE▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Equity	(Dec 31 2025) IV. Quarter	0 III. Quarter	0 II. Quarter	0 I. Quarter	(Dec 31 2024) IV. Quarter
Y / Y Equity Change	-35.19 %	-35.19 %	-43.28 %	-35.19 %	-
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in Millions	-99	-86	-86	-78	-78
Return On Equity (TTM)	-103.25 %	-78.45 %	-69.72 %	-56.24 %	-51.17 %
MOLN's Total Ranking	# 4011	# 0	#	#	#
Equity (TTM) in Millions	101	101	80	101	156
Seq. Equity Change	-0 %	26.01 %	-20.64 %	-35.19 %	-0 %
Seq. Net Income Change	-	-	-	-	-

Back to MOLN Management Effectiveness >> MOLN's 5 Years Annual ROE >> Compare MOLN ROE to its Competitors

Return On Equity Company Ranking
Within:	No.
Industry	# 79
Sector	# 568
Overall	# 4011

Return On Equity Statistics
High	Average	Low
50.11 %	-24.98 %	-76.74 %
(Dec 31 2022)		(Dec 31 2025)

News about Molecular Partners Ag Return on Equity ROE

Precision Immunotherapy How CD3 Switch-DARPin T Cell Engager is Poised to Transform Cancer Treatment with ...

In the ever-evolving field of cancer immunotherapy, the search for innovative therapies that precisely target tumor cells while minimizing collateral damage to healthy tissue remains a paramount goal. A pioneering stride comes from Molecular Partners AG, which recently unveiled compelling preclinical data for its CD3 Switch-DARPin T Cell Engager platform. This research was presented at the Society for Immunotherapy of Cancer (SITC) 2024 meeting, highlighting a novel approach that could revolutionize immune-based cancer therapies. A New Frontier in T Cell Engagement The CD3 Switch-DARPin platform represents a sophisticated method of engaging T cells, the warrior cells of the immune system, against malignant targets. The presented preclinical proof-of-concept data demonstrates the potential of this platform to activate and amplify T cells specifically in the presence of tumor cells. This is a significant advance, as it addresses a critical challenge in immunotherapy: ensuring that T cell activation occurs selectively at the site of the tumor, thereby reducing off-target effects and enhancing the safety of the treatment.

Molecular Partners' Financial Challenges Threaten Promising Therapeutic Pipeline

Molecular Partners Faces Financial Challenges Amid Promising Pipeline
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass. – Molecular Partners AG, a clinical-stage biotech company specializing in DARPin therapeutics, recently released its Interim Management Statement for the first quarter of 2024. While the company reported progress in its pipeline, concerns loom over its financial performance, as it recorded a substantial net loss of $-62 million during the 12-month period ending in the fourth quarter of 2023.
Molecular Partners negative return on equity (ROE) of -35.13% raises alarm bells for investors and industry observers alike. The company s struggle to generate meaningful profits and deliver consistent returns to shareholders is a cause for concern. When compared to 21 other companies within the Biotechnology and Pharmaceuticals industry, it is evident that Molecular Partners lags behind in terms of ROE. This has resulted in a deterioration in its total ranking, dropping from 0 to 2080 compared to the third quarter of 2023.

MOLN Annual Return On Equity	(Dec 31 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021
Total Equity in Millions	80	142	176	235	117
Y / Y Equity Change	-43.28 %	-19.72 %	-24.98 %	100.47 %	-
Net Income in Millions	-62	-54	-62	118	-64
Y / Y Net Income Change	-	-	-	-	-
Return On Equity	-76.74 %	-38.16 %	-35.13 %	50.11 %	-54.37 %

Back to MOLN Management Effectiveness >> MOLN's 5 Years Annual ROE >> Compare MOLN ROE to its Competitors

More Return On Equity Ratios
Biotechnology & Pharmaceuticals Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
MOLN's' Return on Equity at Yahoo Finance
MOLN's Roe Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for MOLN's Competitors
Subscribers only: Roe for Molecular Partners Ag's Suppliers
Subscribers only: Return On Equity for MOLN's Customers

Companies with similar Return On Equity at Dec 31 2025, within Healthcare Sector

ROE

Date modified: 2026-09-09T12:37:57+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.